Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11
MIAMI, FL, April 25, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high qual
LI, VERU and MRIN Among Pre-market Losers
Veru, EyePoint Pharmaceuticals, SINTX Technologies Among Healthcare Movers
Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) fell sharply during Monday's session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic d
Cisco To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Wells Farg
Oppenheimer Reiterates Outperform on Veru, Lowers Price Target to $5
Oppenheimer analyst Leland Gershell reiterates Veru with a Outperform and lowers the price target from $7 to $5.
Oppenheimer: Reiterates the Veru (VERU.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $5.00.
Oppenheimer: Reiterates the Veru (VERU.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $7.00 to $5.00.
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of JPMorgan Chase & Co. (NYSE:JPM) fell sharply during Friday's session following first-quarter earnings. Net revenue (managed) of $42.5 billion (+8% Y/Y), beating the consensus of $41.8 billi
Veru, Theravance Biopharma, Adial Pharmaceuticals Among Healthcare Movers
NKTR, VERU and EGIO Among Mid-day Movers
12 Consumer Staples Stocks Moving In Tuesday's After-Market Session
GainersFarmer Bros (NASDAQ:FARM) stock increased by 4.8% to $3.48 during Tuesday's after-market session. The company's market cap stands at $73.3 million. Pricesmart (NASDAQ:PSMT) stock moved upwards
Veru Announces Date of 2024 Annual Meeting of Shareholders
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late c
Veru Initiated at Outperform by Raymond James
Veru Initiated at Outperform by Raymond James
Raymond James Initiates Coverage On Veru With Outperform Rating, Announces Price Target of $3
Raymond James analyst Gary Nachman initiates coverage on Veru with a Outperform rating and announces Price Target of $3.
Watching Veru; Traders Circulate Analyst Comments Suggesting Co Could See A Take Out From Large Pharma Due To Effectivr GLP-1; Gives It An Outperform Rating And $3 PT
Watching Veru; Traders Circulate Analyst Comments Suggesting Co Could See A Take Out From Large Pharma Due To Effectivr GLP-1; Gives It An Outperform Rating And $3 PT
Veru Reschedules Annual Meeting of Shareholders
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE)
Veru Inc. Appoints Obesity Expert as Advisor
Booz Allen Wins $550M Contract to Support US Energy Innovation
Press Release: Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for Its Enobosarm Program for High Quality Weight Loss
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss MIAMI, March 12, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a
Reported Earlier, Veru Receives Nasdaq Notice For Delay In Filing Quarterly Report
Reported Earlier, Veru Receives Nasdaq Notice For Delay In Filing Quarterly Report
Veru Announces Notification From Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Veru Inc. (NASDAQ: VERU) today announced that it received a delinquency notification letter ("Notice") from the Listing Qualifications staff of the Nasdaq Stock Market LLC ("Nasdaq") on February 21, 2024 due to the Company's non-compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2023 (the "Form 10-Q").
No Data